1-Methylimidazolidin-2-one → [2,4-Bis(3-methyl-2-oxoimidazolidin-1-yl)phenyl][4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone
반응식
Br[C:2]1[CH:7]=[C:6](Br)[CH:5]=[CH:4][C:3]=1[C:9]([N:11]1[CH2:16][CH2:15][N:14]([C:17]2[C:22]([CH3:23])=[CH:21][C:20]([CH3:24])=[CH:19][N:18]=2)[CH2:13][CH2:12]1)=[O:10].[CH3:25][N:26]1[CH2:30][CH2:29][NH:28][C:27]1=[O:31]>>[CH3:25][N:26]1[CH2:30][CH2:29][N:28]([C:2]2[CH:7]=[C:6]([N:28]3[CH2:29][CH2:30][N:26]([CH3:25])[C:27]3=[O:31])[CH:5]=[CH:4][C:3]=2[C:9]([N:11]2[CH2:16][CH2:15][N:14]([C:17]3[C:22]([CH3:23])=[CH:21][C:20]([CH3:24])=[CH:19][N:18]=3)[CH2:13][CH2:12]2)=[O:10])[C:27]1=[O:31]참가 물질
3
실험 절차
Using (2,4-dibromophenyl)[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone (136 mg) described in Preparation Example 237 and 1-methylimidazolidin-2-one (90 mg) and by the reaction and treatment in the same manner as in Example 536, the title compound (44 mg) was obtained.
출처 및 근거
- ORD 기록
- ord-4496a97bbcf1493998dae19535e768d1